Marizyme, Inc., Engages Dr. Pamela Milla as Advisor to Begin Distribution in South America

DAVENPORT, FLA, April 27, 2020  — Marizyme, Inc. (“Marizyme” or the “Company”), a publicly traded (OTC:MRZM) company focused on acquiring late-stage drug and medical device assets to develop for use in the acute care space, announced today that Dr. Pamela Milla will be joining Marizyme, Inc. on or about May 1, 2020, as special advisor to assist in the Company’s efforts to launch distribution of Duragraft in South America. Dr. Milla is an experienced pharmaceutical and medical devices veteran, with both US and global regulatory and clinical experience in Chile and Latin America.  Dr. Milla has been a leader in the Instituto de Salud Pública (Chilean FDA and CDC) as General Director (2004-2006) and Chief of the Drug Agency (2002-2004 and 2015 -2017).

DuraGraft is a CE-marked and patented product that protects vascular grafts against ischemic injury and is the only product registered and indicated for graft protection and preservation during bypass and other vascular surgeries including Coronary Artery Bypass and Peripheral Bypass surgery.  DuraGraft protects graft tissue from harvesting through anastomosis and is used as a treatment to maintain the structural and functional integrity of free vascular grafts. The use of DuraGraft is associated with reductions of post-CABG complications associated with graft disease and failure: Myocardial Infarction, Repeat Revascularization and MACE.

“We are fortunate to have such a seasoned pharmaceutical and medical device expert join the Marizyme team,” said Nicholas DeVito, Marizyme’s Chief Executive. “Dr. Milla’s experience in Chile brings significant added value to the Company and will help the Company implement our South American growth strategies, first in Chile and then in other countries across the continent.

“I am excited and honored to be joining Marizyme at such an opportune time to introduce Duragraft to South America and save lives.” stated Dr. Milla. “Duragraft has shown significant improvements in Cardiac Bypass patient outcomes and I look forward to assisting Marizyme launch DuraGraft.”

About Marizyme, Inc.

Marizyme, Inc. is a development-stage company dedicated to the commercialization of therapies that address the urgent need relating to higher mortality and costs in the acute care space. Specifically, Marizyme will focus its efforts on developing treatments for disease caused by thrombus infections and pain/neurological conditions. For more information, visit www.marizyme.com.

Forward-Looking Statements

This press release may contain certain forward-looking statements, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. The Company has made every reasonable effort to ensure the information and assumptions on which these statements are based are current, reasonable and complete. However, a variety of factors, many of which are beyond the Company’s control, affect the Company’s operations, performance, business strategy and results and there can be no assurances that the Company’s actual results will not differ materially from those indicated herein. Additional written and oral forward-looking statements may be made by the Company from time to time. Forward-looking statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, including those risks set forth in the Company’s risk factor disclosure in its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the Securities and Exchange Commission (SEC File No. 000-53223), uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact

Nicholas DeVito

732-723-7395